<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003687</url>
  </required_header>
  <id_info>
    <org_study_id>19702A</org_study_id>
    <nct_id>NCT05003687</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Lu AG06474 in Healthy Young Men</brief_title>
  <official_title>Interventional, Randomized, Double-Blind, Sequential-Group, Placebo-Controlled, Single-Ascending Oral Dose Study Investigating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Lu AG06474 and Open-Label, Cross-Over Study to Investigate Intra-Subject Variability and the Effect of Food in Healthy Young Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of Lu AG06474 and&#xD;
      what the body does to Lu AG06474 after swallowing single doses of the drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A: randomized, double-blind, sequential. Part B: randomized, open-label, cross-over.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2021</start_date>
  <completion_date type="Anticipated">May 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part A: randomized, double-blind, sequential. Part B: randomized, open-label, cross-over.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parts A and B: Number of participants With Treatment-Emergent Adverse Events</measure>
    <time_frame>From Baseline to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Electrocardiogram (ECG) Parameter (Delta QTcF) at 24 Hours on Day 1</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Pre-Dose Baseline in ECG Parameter (Delta QTcF) at 24 Hours on Day 1</measure>
    <time_frame>Pre-dose Baseline (Day -1), Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Bond-Lader VAS Dimension Scores at Day 4</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Change From Pre-Dose Baseline in the Bond-Lader VAS Dimension Scores at Day 4</measure>
    <time_frame>Pre-dose Baseline (Day -1), Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Percentage of Peripheral Blood Mononuclear Cells (PBMC)-Mediated Hydrolysis of 2-arachidonolylglycerol (2-AG) Ex Vivo (% of Pre-Dose Measurement of Arachidonic Acid [AA])</measure>
    <time_frame>From pre-dose to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts A and B: AUC0-inf of Lu AG06474</measure>
    <time_frame>From pre-dose to Day 4</time_frame>
    <description>Area under the Lu AG06474 concentration-time curve from time zero to infinity (AUC0-inf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts A and B: Cmax of Lu AG06474</measure>
    <time_frame>From pre-dose to Day 4</time_frame>
    <description>Maximum observed plasma concentration for Lu AG06474</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts A and B: Tmax of Lu AG06474</measure>
    <time_frame>From pre-dose to Day 4</time_frame>
    <description>Nominal time corresponding to the occurrence of Cmax of Lu AG06474</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: t1/2 of Lu AG06474</measure>
    <time_frame>From pre-dose to Day 4</time_frame>
    <description>Apparent elimination half-life of Lu AG06474</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A: Single Dose of Lu AG06474 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single oral dose of Lu AG06474 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Repeated Dose of Lu AG06474 and Food Interaction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of Lu AG06474 in each dosing period (Period 1, 2, and 3) in the following sequence:&#xD;
Sequence B1: Fed - Fasting- Fasting&#xD;
Sequence B2: Fasting- Fed - Fasting&#xD;
Sequence B3: Fasting- Fasting - Fed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AG06474</intervention_name>
    <description>solution, orally (Parts A and B)</description>
    <arm_group_label>Part A: Single Dose of Lu AG06474 or Placebo</arm_group_label>
    <arm_group_label>Part B: Repeated Dose of Lu AG06474 and Food Interaction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>solution, orally (Part A only)</description>
    <arm_group_label>Part A: Single Dose of Lu AG06474 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant has a body mass index (BMI) ≥18.5 and ≤30 kilograms (kg)/square meter&#xD;
             (m^2) at the Screening Visit and at the Safety Baseline/Baseline Visit.&#xD;
&#xD;
          -  The participant is, in the opinion of the investigator, generally healthy based on&#xD;
             medical history, a physical examination, vital signs, a safety ECG, and the results of&#xD;
             the clinical chemistry, haematology, urinalysis, serology, and other laboratory tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participant has taken disallowed medication &lt;1 week prior to the first dose of&#xD;
             study drug or &lt;5 half-lives prior to the Screening Visit for any medication taken.&#xD;
&#xD;
          -  The participant has orthostatic hypotension, defined as a decrease in systolic blood&#xD;
             pressure ≥20 millimeters of mercury (mmHg) and/or a decrease in diastolic blood&#xD;
             pressure ≥10 mmHg from supine to standing, at the Screening Visit or at the Safety&#xD;
             Baseline/Baseline Visit.&#xD;
&#xD;
          -  The participant has a QTcF interval &gt;450 milliseconds (ms) at the Screening Visit or&#xD;
             at the Safety Baseline/Baseline Visit, as calculated by the ECG equipment and&#xD;
             evaluated by the investigator.&#xD;
&#xD;
          -  The participant has taken any investigational medicinal product &lt;3 months prior to the&#xD;
             first dose of study drug.&#xD;
&#xD;
          -  The participant has received an injection of COVID-19 vaccination less than 30 days&#xD;
             prior to the first dose of study drug.&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>H. Lundbeck A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Quotient Sciences Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

